Key Details
Price
$14.91Annual Revenue
$50.00 MAnnual ROE
-33.44%Beta
1.87Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 29, 2024Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
07 Nov '24 RBC Capital
Outperform22 Oct '24 Baird
Outperform14 Aug '24 RBC Capital
Outperform30 Apr '24 Stifel
Buy30 Apr '24 RBC Capital
Outperform30 Apr '24 Morgan Stanley
OverweightMarket Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Contineum Therapeutics Class A Common Stock doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
CTNM
businesswire.com04 June 2024
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that Company management will participate in the 45th Annual Goldman Sachs Healthcare Conference, taking place June 10-13, 2024.
U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings
CTNM
Seeking Alpha06 April 2024
U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings
CTNM Stock: 7 Things to Know as Contineum Therapeutics Starts Trading Today
CTNM
InvestorPlace05 April 2024
Contineum Therapeutics (NASDAQ:CTNM) stock is a hot topic among traders on Friday as they prepare for the clinical-stage biopharmaceutical company's shares to go public today. Let's go over everything traders need to know about Contineum Therapeutics ahead of its initial public offering ( IPO ) later today!
FAQ
- What is the primary business of Contineum Therapeutics Class A Common Stock?
- What is the ticker symbol for Contineum Therapeutics Class A Common Stock?
- Does Contineum Therapeutics Class A Common Stock pay dividends?
- What sector is Contineum Therapeutics Class A Common Stock in?
- What industry is Contineum Therapeutics Class A Common Stock in?
- What country is Contineum Therapeutics Class A Common Stock based in?
- Is Contineum Therapeutics Class A Common Stock in the S&P 500?
- Is Contineum Therapeutics Class A Common Stock in the NASDAQ 100?
- Is Contineum Therapeutics Class A Common Stock in the Dow Jones?
- When was Contineum Therapeutics Class A Common Stock's last earnings report?
- When does Contineum Therapeutics Class A Common Stock report earnings?
- Should I buy Contineum Therapeutics Class A Common Stock stock now?
What is the primary business of Contineum Therapeutics Class A Common Stock?
Contineum Therapeutics focuses on developing innovative therapies for chronic diseases. The company leverages advanced biotechnology to create targeted treatments, aiming to improve patient outcomes and enhance quality of life. Their research emphasizes precision medicine and cutting-edge drug delivery systems.
What is the ticker symbol for Contineum Therapeutics Class A Common Stock?
The ticker symbol for Contineum Therapeutics Class A Common Stock is NASDAQ:CTNM
Does Contineum Therapeutics Class A Common Stock pay dividends?
No, Contineum Therapeutics Class A Common Stock does not pay dividends
What sector is Contineum Therapeutics Class A Common Stock in?
Contineum Therapeutics Class A Common Stock is in the Healthcare sector
What industry is Contineum Therapeutics Class A Common Stock in?
Contineum Therapeutics Class A Common Stock is in the Biotechnology industry
What country is Contineum Therapeutics Class A Common Stock based in?
Contineum Therapeutics Class A Common Stock is headquartered in United States
Is Contineum Therapeutics Class A Common Stock in the S&P 500?
No, Contineum Therapeutics Class A Common Stock is not included in the S&P 500 index
Is Contineum Therapeutics Class A Common Stock in the NASDAQ 100?
No, Contineum Therapeutics Class A Common Stock is not included in the NASDAQ 100 index
Is Contineum Therapeutics Class A Common Stock in the Dow Jones?
No, Contineum Therapeutics Class A Common Stock is not included in the Dow Jones index
When was Contineum Therapeutics Class A Common Stock's last earnings report?
Contineum Therapeutics Class A Common Stock's most recent earnings report was on 29 November 2024
When does Contineum Therapeutics Class A Common Stock report earnings?
The date for Contineum Therapeutics Class A Common Stock's next earnings report has not been announced yet
Should I buy Contineum Therapeutics Class A Common Stock stock now?
As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions